Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs

Background: Despite atezolizumab and bevacizumab (A + B) is currently the first-line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have been proposed as prognostic factors. Objective: To...

Full description

Bibliographic Details
Authors: Díaz González, Álvaro, Sapena, Victor, Boix i Ferrero, Loreto, Torres, Ferran, Sanduzzi Zamparelli, Marco, Da Fonseca, Leonardo G., Llarch, Neus, Iserte, Gemma, Guedes, Cassia, Muñoz Martínez, Sergio Gabriel, Darnell, Anna, Belmonte, Ernest, Rimola Gibert, Jordi, Forner, Alejandro, Ayuso Colella, Carmen, Bruix Tudó, Jordi, Reig, María
Format: article
Status:Published version
Publication Date:2021
Country:España
Institution:Universidad de Barcelona
Repository:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/200305
Online Access:https://hdl.handle.net/2445/200305
Access Level:Open access
Keyword:Hepatologia
Cèl·lules canceroses
Càncer de fetge
Diarrea
Resistència als medicaments
Anàlisi de supervivència (Biometria)
Proteïna-tirosina-fosfatasa
Proteïnes quinases
Inhibició
Hepatology
Cancer cells
Liver cancer
Diarrhea
Drug resistance
Survival analysis (Biometry)
Protein-tyrosine phosphatase
Protein kinases
Inhibition
id ES_cca95f4f272bb9249d533201c96fbfb2
oai_identifier_str oai:diposit.ub.edu:2445/200305
network_acronym_str ES
network_name_str España
repository_id_str
spelling Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugsDíaz González, ÁlvaroSapena, VictorBoix i Ferrero, LoretoTorres, FerranSanduzzi Zamparelli, MarcoDa Fonseca, Leonardo G.Llarch, NeusIserte, GemmaGuedes, CassiaMuñoz Martínez, Sergio GabrielDarnell, AnnaBelmonte, ErnestRimola Gibert, JordiForner, AlejandroAyuso Colella, CarmenBruix Tudó, JordiReig, MaríaHepatologiaCèl·lules cancerosesCàncer de fetgeDiarreaResistència als medicamentsAnàlisi de supervivència (Biometria)Proteïna-tirosina-fosfatasaProteïnes quinasesInhibicióHepatologyCancer cellsLiver cancerDiarrheaDrug resistanceSurvival analysis (Biometry)Protein-tyrosine phosphataseProtein kinasesInhibitionBackground: Despite atezolizumab and bevacizumab (A + B) is currently the first-line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have been proposed as prognostic factors. Objective: To characterize the early diarrhoea development as prognostic factor in 344 HCC patients. Methods: The development of early diarrhoea in sorafenib treatment defined as patients who developed diarrhoea and needed dose modification within the first 60 days of treatment (e-diarrhoea) and 3-grouping variables were analysed: Patients with e-diarrhoea, patients who developed diarrhoea after the first 60 days of treatment (L-diarrhoea) and patients that never developed diarrhoea (never diarrhoea). Results: The median overall survival in sorafenib treated patients was significantly different across groups (6.8 months for e-diarrhoea, 26.7 months for L-diarrhoea and 13.3 months for never-diarrhoea). The emergence of e-diarrhoea was associated with poor outcomes (hazard ratio [HR] 1.84 [95%CI 1.15-2.95]), while there was no increased/decreased risk of dismal evolution in patients with L-diarrhoea (HR 0.66 [95%CI 0.42-1.03]). Conclusion: The emergence of e-diarrhoea in HCC patients treated with sorafenib is an early predictor of dismal evolution under this therapy. Thus, prompt identification of these non-responders may be useful for an early switch to second-line therapies.SAGE Publications2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/200305Articles publicats en revistes (Fonaments Clínics)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1002/ueg2.12111United European Gastroenterology Journal, 2021, vol. 9, num. 9, p. 655-661https://doi.org/10.1002/ueg2.12111cc by- nc-nd (c) Díaz González, Álvaro et al., 2021http://creativecommons.org/licenses/by-nc-nd/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/2003052026-05-27T06:46:51Z
dc.title.none.fl_str_mv Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs
title Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs
spellingShingle Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs
Díaz González, Álvaro
Hepatologia
Cèl·lules canceroses
Càncer de fetge
Diarrea
Resistència als medicaments
Anàlisi de supervivència (Biometria)
Proteïna-tirosina-fosfatasa
Proteïnes quinases
Inhibició
Hepatology
Cancer cells
Liver cancer
Diarrhea
Drug resistance
Survival analysis (Biometry)
Protein-tyrosine phosphatase
Protein kinases
Inhibition
title_short Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs
title_full Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs
title_fullStr Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs
title_full_unstemmed Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs
title_sort Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs
dc.creator.none.fl_str_mv Díaz González, Álvaro
Sapena, Victor
Boix i Ferrero, Loreto
Torres, Ferran
Sanduzzi Zamparelli, Marco
Da Fonseca, Leonardo G.
Llarch, Neus
Iserte, Gemma
Guedes, Cassia
Muñoz Martínez, Sergio Gabriel
Darnell, Anna
Belmonte, Ernest
Rimola Gibert, Jordi
Forner, Alejandro
Ayuso Colella, Carmen
Bruix Tudó, Jordi
Reig, María
author Díaz González, Álvaro
author_facet Díaz González, Álvaro
Sapena, Victor
Boix i Ferrero, Loreto
Torres, Ferran
Sanduzzi Zamparelli, Marco
Da Fonseca, Leonardo G.
Llarch, Neus
Iserte, Gemma
Guedes, Cassia
Muñoz Martínez, Sergio Gabriel
Darnell, Anna
Belmonte, Ernest
Rimola Gibert, Jordi
Forner, Alejandro
Ayuso Colella, Carmen
Bruix Tudó, Jordi
Reig, María
author_role author
author2 Sapena, Victor
Boix i Ferrero, Loreto
Torres, Ferran
Sanduzzi Zamparelli, Marco
Da Fonseca, Leonardo G.
Llarch, Neus
Iserte, Gemma
Guedes, Cassia
Muñoz Martínez, Sergio Gabriel
Darnell, Anna
Belmonte, Ernest
Rimola Gibert, Jordi
Forner, Alejandro
Ayuso Colella, Carmen
Bruix Tudó, Jordi
Reig, María
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Hepatologia
Cèl·lules canceroses
Càncer de fetge
Diarrea
Resistència als medicaments
Anàlisi de supervivència (Biometria)
Proteïna-tirosina-fosfatasa
Proteïnes quinases
Inhibició
Hepatology
Cancer cells
Liver cancer
Diarrhea
Drug resistance
Survival analysis (Biometry)
Protein-tyrosine phosphatase
Protein kinases
Inhibition
topic Hepatologia
Cèl·lules canceroses
Càncer de fetge
Diarrea
Resistència als medicaments
Anàlisi de supervivència (Biometria)
Proteïna-tirosina-fosfatasa
Proteïnes quinases
Inhibició
Hepatology
Cancer cells
Liver cancer
Diarrhea
Drug resistance
Survival analysis (Biometry)
Protein-tyrosine phosphatase
Protein kinases
Inhibition
description Background: Despite atezolizumab and bevacizumab (A + B) is currently the first-line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have been proposed as prognostic factors. Objective: To characterize the early diarrhoea development as prognostic factor in 344 HCC patients. Methods: The development of early diarrhoea in sorafenib treatment defined as patients who developed diarrhoea and needed dose modification within the first 60 days of treatment (e-diarrhoea) and 3-grouping variables were analysed: Patients with e-diarrhoea, patients who developed diarrhoea after the first 60 days of treatment (L-diarrhoea) and patients that never developed diarrhoea (never diarrhoea). Results: The median overall survival in sorafenib treated patients was significantly different across groups (6.8 months for e-diarrhoea, 26.7 months for L-diarrhoea and 13.3 months for never-diarrhoea). The emergence of e-diarrhoea was associated with poor outcomes (hazard ratio [HR] 1.84 [95%CI 1.15-2.95]), while there was no increased/decreased risk of dismal evolution in patients with L-diarrhoea (HR 0.66 [95%CI 0.42-1.03]). Conclusion: The emergence of e-diarrhoea in HCC patients treated with sorafenib is an early predictor of dismal evolution under this therapy. Thus, prompt identification of these non-responders may be useful for an early switch to second-line therapies.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/200305
url https://hdl.handle.net/2445/200305
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1002/ueg2.12111
United European Gastroenterology Journal, 2021, vol. 9, num. 9, p. 655-661
https://doi.org/10.1002/ueg2.12111
dc.rights.none.fl_str_mv cc by- nc-nd (c) Díaz González, Álvaro et al., 2021
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by- nc-nd (c) Díaz González, Álvaro et al., 2021
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv SAGE Publications
publisher.none.fl_str_mv SAGE Publications
dc.source.none.fl_str_mv Articles publicats en revistes (Fonaments Clínics)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419740157444096
score 15.301603

Similar Items